Navigation Links
DiaTech Life Sciences Announces Medical Advisory Board
Date:11/30/2011

NASHVILLE, Tenn., Nov. 30, 2011 /PRNewswire/ -- DiaTech Life Sciences has announced the formation of a Medical Advisory Council to advance the use of the Microculture Kinetic (MiCK) assay for apoptosis, a new assay designed to predict which chemotherapy is most effective for cancer patients. DiaTech has introduced this technology for individual patient testing and recently developed a model to assist pharmaceutical companies in validating new drugs that may be more effective.

Franklyn G. Prendergast M.D., Ph.D., will lead the Advisory Board. Dr. Prendergast obtained his medical degree (with honors) from University of the West Indies in 1968, his BA and MA in Physiology from the University of Oxford (as a Rhodes Scholar) and Ph.D. in Biochemistry from Mayo Graduate School/University of Minnesota. He has been on staff of the Mayo Clinic since 1977 and has served in many scientific and administrative capacities there, most notably: Chair, Department of Biochemistry and Molecular Biology; Mayo Clinic Rochester Board of Governors; Mayo Clinic Board of Governors; Mayo Foundation's Board of Trustees; Director, Mayo Clinic Comprehensive Cancer Center; Director, Mayo Clinic Center for Individualized Medicine. He has been the Edmond and Marion Guggenheim Professor of Biochemistry and Molecular Biology since 1986. He also has an extensive history on review and advisory committees of the National Institutes of Health and has been a member of the Board of Directors of Eli Lilly and Co since 1996. Dr. Prendergast has published more than 300 papers and abstracts.

Roy S. Herbst M.D., Ph.D., will also join the DiaTech Advisory Board. He recently accepted the position to lead medical oncology at Smilow Cancer Hospital at Yale-New Haven and was previously at University of Texas MD Anderson Cancer Center. Dr. Herbst is best known for his work in linking genetic abnormalities of cancer cells to novel therapies. Dr. Herbst received his medical degree from Cornell University Medical College and earned a Ph.D. in molecular cell biology from Rockefeller University. He completed his medical oncology fellowship at Dana Farber Cancer Institute and a medical hematology fellowship at Brigham and Women's Hospital in Boston, where he also received a master's degree from Harvard University for Clinical Investigation.

Martin Fleisher, Ph.D., Chief of the Clinical Chemistry Service and Director of the Biomarker Discovery Laboratory at the Memorial Sloan-Kettering Cancer Center in New York City will also join the DiaTech team. Dr. Fleisher is an international expert in the discovery and use of tumor markers and biomarkers for detecting and monitoring various types of cancers. Dr. Fleisher has been awarded three patents by the United States, European, and Australian patent offices for test procedures in the area of cancer screening. His research interests in analytical methodologies include enzymes as diagnostic tools, discovery and validation of biomarkers for monitoring therapeutic efficacy in cancer, and in the clinical use of circulating tumor cells in drug development. Dr. Fleisher has published over 70 papers, including five chapters on his research, and has edited a book on the Clinical Biochemistry of Cancer.

"The DiaTech MiCK assay is an impressive technology that may work on all cancers and the only test we know of in the market that can tell the most effective chemotherapy for inducing apoptosis (cell death) in the malignant cells of a particular patient. We may have therefore a unique opportunity to improve the treatment of cancer patients. Furthermore, this technology may be useful as a tool for pharmaceutical companies to improve the drug discovery cycle," said Dr. Frank Prendergast, Emeritus Director for Clinic for Individualized Medicine at Mayo Clinic and Emeritus Trustee of the Mayo Foundation.

The Microculture Kinetic (MiCK) assay for apoptosis is an advanced novel technology that measures the precise timing and extent of apoptosis induced in tumor cells by chemotherapy drugs or experimental anticancer drugs either as monotherapy or in drug combination. Because of this unique capability, the MiCK assay can be a valuable tool in the field of drug discovery by reducing the costs associated with validation studies and the time required to obtain FDA approval.

Contact:

Steve Latimer
1-866-556-5356
info@diatechoncology.com
http://www.diatech-oncology.com

 

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE DiaTech Life Sciences
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. DiaTech Oncology and Walter Reed Army Medical Center Establish Pilot to Determine Best Chemotherapy for Cancer Patients
2. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
3. Garage Start-ups Now Possible in Life Sciences Industry
4. Sangamo BioSciences Announces Presentation at the Lazard Capital Markets 8th Annual Healthcare Conference
5. Regado Biosciences, Inc. Presents Positive Efficacy and Safety Substudy Data from the Phase 2b RADAR Trial for the REG1 Anticoagulation System at the Transcatheter Cardiovascular Therapeutics (TCT) Symposium 2011
6. Caliper Life Sciences Reports Third Quarter 2011 Results
7. Axia Value Chain Appoints John Christina Managing Director of Life Sciences Practice
8. Human Genome Sciences Europe Moves to the Cloud With Veeva CRM to Support New Lupus Treatment
9. Neurocrine Biosciences Reports Third Quarter 2011 Results
10. BioCrossroads Awards Indiana Life Sciences Leaders
11. Sangamo BioSciences Reports Third Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2020)... ... 29, 2020 , ... The Conference Forum is pleased to ... to the unique role of the Chief Medical Officer in the biotech industry. ... best practices and career development of CMOs and Heads of R&D from different ...
(Date:5/26/2020)... , ... May 26, 2020 , ... Brilliant , ... recognized brand of smart garage door openers, announce a new integration to bring more ... enabled garage door openers powered by Aladdin Connect® can now be controlled from Brilliant’s ...
(Date:5/21/2020)... , ... May 19, 2020 , ... Eaton Square is ... addition of Popper and Company, a biotechnology and medical technology-focused strategy and M&A advisory ... grow in the United States, linking US and Asia Pacific healthcare innovators with capital ...
(Date:5/15/2020)... ... May 14, 2020 , ... Children with ... heart surgeries before becoming adults. The reason: there are no heart valve ... unmet need, the Department of Defense has awarded Draper, Boston Children’s Hospital and ...
Breaking Biology Technology:
(Date:5/28/2020)... ... May 27, 2020 , ... ... Advisor™ , a solution that uniquely combines lab testing insights and hc1’s exclusive ... support the ongoing health and safety of employees returning to the workplace. , ...
(Date:5/21/2020)... , ... May 21, 2020 ... ... Capital IntegritySM technology-based services specializing in background and medical screening, announces the ... return-to-work planning and keeping their workforce safe. The new service is provided ...
(Date:5/15/2020)... ... May 15, 2020 , ... The National Institutes of Health (NIH) has ... in Frederick, Maryland and Tysons Corner, Virginia, to provide patent legal services under two ... in the field of chemistry. The firm is one of nine firms in the ...
Breaking Biology News(10 mins):